BofA lowered the firm’s price target on Caris Life Sciences (CAI) to $35 from $39 and keeps a Buy rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Hold at Canaccord
- Caris Life Sciences Reports Record Revenue Growth
- Caris Life Sciences, Inc.: Strong Financial Performance and Promising Future Justify Buy Rating
- Caris Life Sciences Reports Strong Q3 2025 Growth
- Closing Bell Movers: Qualcomm down 3%, Robinhood slips 2% on earnings